No question about that (IMO), but the salient point is that no one will want to administer PD-(L)1 agents indefinitely the way nukes are currently used to treat chronic HBV. Hence, unless PD-(L)1 agents can be a component of some kind of curative regimen, they won’t have any commercial role to play in HBV.
Thanks for the references.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.